BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

739 related articles for article (PubMed ID: 11504908)

  • 1. Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR.
    Neshat MS; Mellinghoff IK; Tran C; Stiles B; Thomas G; Petersen R; Frost P; Gibbons JJ; Wu H; Sawyers CL
    Proc Natl Acad Sci U S A; 2001 Aug; 98(18):10314-9. PubMed ID: 11504908
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enhanced sensitivity of multiple myeloma cells containing PTEN mutations to CCI-779.
    Shi Y; Gera J; Hu L; Hsu JH; Bookstein R; Li W; Lichtenstein A
    Cancer Res; 2002 Sep; 62(17):5027-34. PubMed ID: 12208757
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of the mammalian target of rapamycin inhibitor CCI-779 used alone or with chemotherapy on human prostate cancer cells and xenografts.
    Wu L; Birle DC; Tannock IF
    Cancer Res; 2005 Apr; 65(7):2825-31. PubMed ID: 15805283
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibitors of mTOR reverse doxorubicin resistance conferred by PTEN status in prostate cancer cells.
    Grünwald V; DeGraffenried L; Russel D; Friedrichs WE; Ray RB; Hidalgo M
    Cancer Res; 2002 Nov; 62(21):6141-5. PubMed ID: 12414639
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity in Pten+/- mice.
    Podsypanina K; Lee RT; Politis C; Hennessy I; Crane A; Puc J; Neshat M; Wang H; Yang L; Gibbons J; Frost P; Dreisbach V; Blenis J; Gaciong Z; Fisher P; Sawyers C; Hedrick-Ellenson L; Parsons R
    Proc Natl Acad Sci U S A; 2001 Aug; 98(18):10320-5. PubMed ID: 11504907
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacogenomic profiling of the PI3K/PTEN-AKT-mTOR pathway in common human tumors.
    Xu G; Zhang W; Bertram P; Zheng XF; McLeod H
    Int J Oncol; 2004 Apr; 24(4):893-900. PubMed ID: 15010827
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modulation of hypoxia-inducible factor 1alpha expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics.
    Zhong H; Chiles K; Feldser D; Laughner E; Hanrahan C; Georgescu MM; Simons JW; Semenza GL
    Cancer Res; 2000 Mar; 60(6):1541-5. PubMed ID: 10749120
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phosphatidylinositol 3-kinase/Akt/mTOR pathway mediates and PTEN antagonizes tumor necrosis factor inhibition of insulin signaling through insulin receptor substrate-1.
    Ozes ON; Akca H; Mayo LD; Gustin JA; Maehama T; Dixon JE; Donner DB
    Proc Natl Acad Sci U S A; 2001 Apr; 98(8):4640-5. PubMed ID: 11287630
    [TBL] [Abstract][Full Text] [Related]  

  • 9. FRAP-p70s6K signaling is required for pancreatic cancer cell proliferation.
    Shah SA; Potter MW; Ricciardi R; Perugini RA; Callery MP
    J Surg Res; 2001 May; 97(2):123-30. PubMed ID: 11341787
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of the phosphatidylinositol 3-kinase/Akt and mTOR/P70S6-kinase pathways in the proliferation and apoptosis in multiple myeloma.
    Pene F; Claessens YE; Muller O; Viguié F; Mayeux P; Dreyfus F; Lacombe C; Bouscary D
    Oncogene; 2002 Sep; 21(43):6587-97. PubMed ID: 12242656
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant Akt Activity.
    deGraffenried LA; Friedrichs WE; Russell DH; Donzis EJ; Middleton AK; Silva JM; Roth RA; Hidalgo M
    Clin Cancer Res; 2004 Dec; 10(23):8059-67. PubMed ID: 15585641
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fibronectin stimulates non-small cell lung carcinoma cell growth through activation of Akt/mammalian target of rapamycin/S6 kinase and inactivation of LKB1/AMP-activated protein kinase signal pathways.
    Han S; Khuri FR; Roman J
    Cancer Res; 2006 Jan; 66(1):315-23. PubMed ID: 16397245
    [TBL] [Abstract][Full Text] [Related]  

  • 13. mTOR promotes survival and astrocytic characteristics induced by Pten/AKT signaling in glioblastoma.
    Hu X; Pandolfi PP; Li Y; Koutcher JA; Rosenblum M; Holland EC
    Neoplasia; 2005 Apr; 7(4):356-68. PubMed ID: 15967113
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activation of phosphatidylinositol 3-kinase, protein kinase B, and p70 S6 kinases in lipopolysaccharide-stimulated Raw 264.7 cells: differential effects of rapamycin, Ly294002, and wortmannin on nitric oxide production.
    Salh B; Wagey R; Marotta A; Tao JS; Pelech S
    J Immunol; 1998 Dec; 161(12):6947-54. PubMed ID: 9862729
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Constitutive activation of phosphatidyl-inositide 3 kinase contributes to the survival of Hodgkin's lymphoma cells through a mechanism involving Akt kinase and mTOR.
    Dutton A; Reynolds GM; Dawson CW; Young LS; Murray PG
    J Pathol; 2005 Mar; 205(4):498-506. PubMed ID: 15714459
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Unique, highly proliferative growth phenotype expressed by embryonic and neointimal smooth muscle cells is driven by constitutive Akt, mTOR, and p70S6K signaling and is actively repressed by PTEN.
    Mourani PM; Garl PJ; Wenzlau JM; Carpenter TC; Stenmark KR; Weiser-Evans MC
    Circulation; 2004 Mar; 109(10):1299-306. PubMed ID: 14993145
    [TBL] [Abstract][Full Text] [Related]  

  • 17. mTor is required for hypertrophy of Pten-deficient neuronal soma in vivo.
    Kwon CH; Zhu X; Zhang J; Baker SJ
    Proc Natl Acad Sci U S A; 2003 Oct; 100(22):12923-8. PubMed ID: 14534328
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gas6 induces Akt/mTOR-mediated mesangial hypertrophy in diabetic nephropathy.
    Nagai K; Matsubara T; Mima A; Sumi E; Kanamori H; Iehara N; Fukatsu A; Yanagita M; Nakano T; Ishimoto Y; Kita T; Doi T; Arai H
    Kidney Int; 2005 Aug; 68(2):552-61. PubMed ID: 16014032
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mammalian target of rapamycin pathway regulates insulin signaling via subcellular redistribution of insulin receptor substrate 1 and integrates nutritional signals and metabolic signals of insulin.
    Takano A; Usui I; Haruta T; Kawahara J; Uno T; Iwata M; Kobayashi M
    Mol Cell Biol; 2001 Aug; 21(15):5050-62. PubMed ID: 11438661
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Loss of PTEN expression leading to high Akt activation in human multiple myelomas.
    Hyun T; Yam A; Pece S; Xie X; Zhang J; Miki T; Gutkind JS; Li W
    Blood; 2000 Nov; 96(10):3560-8. PubMed ID: 11071655
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 37.